
Contract partners must help innovators, especially smaller and virtual companies, consider manufacturability as early as possible in development. This requires focusing on technical and operational performance, as well as cost.
Alberto Santagostino is senior vice-president and head of cell and gene technologies at Lonza Pharma and Biotech.

Published: February 6th 2020 | Updated: